MX2007009577A - Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31. - Google Patents
Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31.Info
- Publication number
- MX2007009577A MX2007009577A MX2007009577A MX2007009577A MX2007009577A MX 2007009577 A MX2007009577 A MX 2007009577A MX 2007009577 A MX2007009577 A MX 2007009577A MX 2007009577 A MX2007009577 A MX 2007009577A MX 2007009577 A MX2007009577 A MX 2007009577A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- predicting
- atopic dermatitis
- therpeutic
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Virology (AREA)
Abstract
La presente invencion se refiere a metodos para tratar a pacientes con dermatitis atopica que sufren de comezon y pruritis mediadas por celulas T positivas para antigenos linfocitarios cutaneos. La invencion tambien incluye metodos para predecir una poblacion de pacientes terapeuticamente sensibles.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65311405P | 2005-02-14 | 2005-02-14 | |
US71676205P | 2005-09-13 | 2005-09-13 | |
US74995205P | 2005-12-13 | 2005-12-13 | |
PCT/US2006/005328 WO2006088956A2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007009577A true MX2007009577A (es) | 2008-01-30 |
Family
ID=36685803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007009577A MX2007009577A (es) | 2005-02-14 | 2006-02-14 | Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31. |
MX2007009471A MX2007009471A (es) | 2005-02-14 | 2006-02-14 | Metodos de tratamiento de enfermedades que son mediadas por las celulas positivas al antigeno del linfocito cutaneo. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007009471A MX2007009471A (es) | 2005-02-14 | 2006-02-14 | Metodos de tratamiento de enfermedades que son mediadas por las celulas positivas al antigeno del linfocito cutaneo. |
Country Status (8)
Country | Link |
---|---|
US (11) | US20060188499A1 (es) |
EP (2) | EP1856539B1 (es) |
JP (2) | JP2008530137A (es) |
AU (2) | AU2006214326B2 (es) |
CA (2) | CA2595939C (es) |
IL (3) | IL184734A (es) |
MX (2) | MX2007009577A (es) |
WO (2) | WO2006088956A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2135953B1 (en) | 1999-06-02 | 2014-04-23 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, Nr. 10 |
ES2254224T3 (es) | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
WO2003060090A2 (en) * | 2002-01-18 | 2003-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
US20060228329A1 (en) * | 2005-01-28 | 2006-10-12 | Brady Lowell J | Homogeneous preparations of IL-31 |
MX2007009718A (es) | 2005-02-14 | 2007-09-26 | Zymogenetics Inc | Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra. |
AU2006214326B2 (en) * | 2005-02-14 | 2011-09-29 | National Jewish Medical And Research Center | Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists |
US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
BRPI0611069A2 (pt) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma |
EP2594585A1 (en) | 2006-01-10 | 2013-05-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
UA100116C2 (ru) | 2006-06-08 | 2012-11-26 | Чугей Сейяку Кабусики Кайся | Профилактика или лечение воспалительного заболевания |
ES2548714T3 (es) | 2006-09-01 | 2015-10-20 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y procedimientos de uso |
EP2061496A2 (en) | 2007-01-10 | 2009-05-27 | Zymogenetics, Inc. | Methods of using il-31 to treat airway hyper-responsiveness and asthma |
TWI441649B (zh) * | 2007-12-05 | 2014-06-21 | Chugai Pharmaceutical Co Ltd | Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus |
PT2796466T (pt) * | 2007-12-07 | 2018-02-23 | Zymogenetics Inc | Moléculas de anticorpo humanizado específicas para il-31 |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
WO2014208645A1 (ja) * | 2013-06-28 | 2014-12-31 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のil-31アンタゴニストによる治療に対する応答を予測する方法 |
WO2016167263A1 (ja) * | 2015-04-14 | 2016-10-20 | 中外製薬株式会社 | Il-31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物 |
AU2016248786B2 (en) | 2015-04-14 | 2022-01-20 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient |
US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
BR112020017715A2 (pt) | 2018-03-16 | 2020-12-29 | Zoetis Services Llc | Vacinas de peptídeo contra interleucina-31 |
CN112020511A (zh) | 2018-03-16 | 2020-12-01 | 硕腾服务有限责任公司 | 用于兽医用途的白介素-31单克隆抗体 |
JP2021522241A (ja) * | 2018-04-25 | 2021-08-30 | キニクサ ファーマシューティカルズ, リミテッド | 抗osmrβ抗体の送達による皮膚疾患又は障害の治療 |
CN117018202A (zh) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
RU2707181C1 (ru) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови |
KR102416078B1 (ko) | 2019-11-20 | 2022-07-01 | 추가이 세이야쿠 가부시키가이샤 | 항체 함유 제제 |
KR102392954B1 (ko) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도 |
EP4209227A4 (en) | 2020-09-01 | 2024-05-29 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF PRURITUS IN DIALYSIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE INGREDIENT |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
US20040235955A1 (en) * | 2001-09-14 | 2004-11-25 | Masami Narita | Remedies for pruritus |
WO2003060090A2 (en) * | 2002-01-18 | 2003-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
SI1576112T1 (sl) * | 2002-01-18 | 2012-10-30 | Zymogenetics Inc | Multimerni citokinski receptor zcitor17 |
JP2004219390A (ja) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法 |
CN1610552A (zh) | 2002-02-22 | 2005-04-27 | 大正制药株式会社 | 止痒剂 |
JP2004107209A (ja) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | 掻痒治療薬 |
JP4503942B2 (ja) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | 止痒剤 |
EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
US20060228329A1 (en) | 2005-01-28 | 2006-10-12 | Brady Lowell J | Homogeneous preparations of IL-31 |
AU2006214326B2 (en) | 2005-02-14 | 2011-09-29 | National Jewish Medical And Research Center | Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists |
MX2007009718A (es) * | 2005-02-14 | 2007-09-26 | Zymogenetics Inc | Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra. |
BRPI0611069A2 (pt) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma |
US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
JP5018481B2 (ja) * | 2005-09-28 | 2012-09-05 | コニカミノルタアドバンストレイヤー株式会社 | 射出成形装置 |
EP2594585A1 (en) | 2006-01-10 | 2013-05-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
ES2548714T3 (es) | 2006-09-01 | 2015-10-20 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y procedimientos de uso |
EP2061496A2 (en) | 2007-01-10 | 2009-05-27 | Zymogenetics, Inc. | Methods of using il-31 to treat airway hyper-responsiveness and asthma |
PT2796466T (pt) * | 2007-12-07 | 2018-02-23 | Zymogenetics Inc | Moléculas de anticorpo humanizado específicas para il-31 |
-
2006
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en active Application Filing
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/es active IP Right Grant
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Not-in-force
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en active Application Filing
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/ja active Pending
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/ja not_active Expired - Fee Related
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/es not_active Application Discontinuation
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en active Active
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en active Active
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en active Active
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en active Active
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007009577A (es) | Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31. | |
JP2008530138A5 (es) | ||
TW200716676A (en) | Therapeutic human anti-IL-1R1 monoclonal antibody | |
TW200637574A (en) | Treatment method | |
CY1112912T1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
MA33717B1 (fr) | Immunoconjugués ciblés | |
MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
Mori et al. | Cutaneous hypersensitivities to hapten are controlled by IFN-γ-upregulated keratinocyte Th1 chemokines and IFN-γ-downregulated langerhans cell Th2 chemokines | |
MXPA05008648A (es) | Usos y formulaciones para la aplicacion transdermica o transmucosa de agentes activos. | |
MY147217A (en) | Antibody molecules having specificity for human il-06 | |
IN2012DN02753A (es) | ||
NZ590994A (en) | Anti il-7r antibodies treatment of autoimmune and inflammatory disease | |
MX2009009283A (es) | Anticuerpos anti-interleuquina -23r de ingenieria. | |
MX353143B (es) | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. | |
ATE452908T1 (de) | Il-10 mutante | |
NZ710459A (en) | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 | |
MA31838B1 (fr) | Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations | |
EA201000265A1 (ru) | Мутанты mcp-1 антагонисты гликозаминогликана и способы их применения | |
ATE545422T1 (de) | Beta-glycolipide als immunomodulatoren | |
MY141851A (en) | Human monoclonal antibodies against human il-4 | |
TW200633726A (en) | Uses of mammalian cytokine; related reagents | |
ATE479678T1 (de) | Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors | |
MX2010001307A (es) | Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos. | |
MA38930A1 (fr) | Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r) | |
UA105384C2 (ru) | Лечение нарушений, связанных с инсулинорезистентностью |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |